EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Application based on results of pivotal phase 3 QuANTUM-R study of quizartinib in patients with relapsed/refractory FLT3-ITD AML
Quizartinib is the first FLT3 inhibitor to demonstrate a survival benefit in a randomized phase 3 study in patients with rel... Biopharmaceuticals, Oncology, Regulatory Daiichi Sankyo, quizartinib, acute myeloid leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Grants | Leukemia | Marketing | Pharmaceuticals | Study